BPA Call 75F40121A00003-75F40122F19001

Ended Awarded Last action

Contract number
75F40122F19001
Awardee
Awarding agency
Obligated
$5,566,265

Award facts

Contract value 94% obligated
  • $5,566,264.64 Current, with exercised options
  • $5,898,997.04 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Calverton, MD 20705, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Terminate for Convenience P00013 · EOI::top 10 consulting firms::EOI notice of termination for convenience agreement - FDA enterprise risk management program support -$973,183
Terminate for Convenience P00012 · EOI::top 10 consulting firms::EOI notice of termination for convenience $0
Exercise an Option P00011 $1,255,721
Funding Only Action P00010 $0
Exercise an Option P00009 $1,568,385
Funding Only Action P00008 $385,267
Funding Only Action P00007 $487,731
Other Administrative Action P00006 · FDA enterprise risk management program support $1,377,831
Supplemental Agreement for work within scope P00005 $272,449
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $1,192,065
Show all 14

About this award

Deloitte Consulting LLP was awarded a $5.9 million Blanket Purchase Agreement (BPA) call under the Food and Drug Administration's Enterprise Risk Management Program Support initiative, with an ultimate completion date of July 21, 2025. The contract, which commenced November 30, 2021, carries no small business set-aside designation and operates under a firm fixed-price pricing structure. The work is being performed at Deloitte's location in Calverton, Maryland. This award represents a child contract under Deloitte's broader General Services Administration Multiple Award Schedule vehicle, leveraging the firm's established capacity to provide enterprise-level consulting services to federal agencies. The FDA's Enterprise Risk Management Program focuses on identifying, assessing, and mitigating organizational risks across the agency's operations and regulatory functions.

Deloitte has engaged multiple subcontractors to support delivery under this contract, including several small business firms certified under the SBA's 8(a) program and other federal contracting preferences. Recurring subcontractors include Lanevis, LLC, a minority-owned 8(a) program participant specializing in technical support and documentation services; Vergys LLC, a minority-owned small disadvantaged business providing governance and management consulting; Agisol LLC, a woman-owned 8(a) certified firm with expertise in IT services; Lynch Consultants, LLC, a service-disabled veteran-owned small business delivering financial and audit readiness support; and Schaffer Consulting LLC. These subcontractors provide procurement support and ancillary services aligned with the statement of work, with subcontract awards spanning from August 2022 through March 2024.

Quick answers

Who was awarded contract 75F40122F19001?

75F40122F19001 was awarded to Deloitte Consulting LLP by Food and Drug Administration (Department of Health and Human Services) on November 30, 2021.

How much is contract 75F40122F19001 worth?

The government has obligated $5,566,265 on 75F40122F19001. Its potential value, with all options, is $5,898,997.

Is contract 75F40122F19001 an order under another contract?

Yes. 75F40122F19001 is a BPA call under 47QRAA18D001P-75F40121A00003, a blanket purchase agreement, on Multiple Award Schedule (MAS).

Was contract 75F40122F19001 competed?

The extent of competition for 75F40122F19001 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award